ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "longitudinal studies"

  • Abstract Number: 1575 • ACR Convergence 2022

    Characteristics of an Internet-Based, International Cohort of Patients with a Self-Reported Diagnosis of Urticarial Vasculitis

    Jason Springer1, Tanaz Kermani2, Dianne Shaw3, Kalen Larson4, Cristina Burroughs5 and Peter Merkel6, 1Vanderbilt University Medical Center, Nashville, TN, 2University of California Los Angeles, Los Angeles, CA, 3Vasculitis Foundation, Chapel Hill, NC, 4Vasculitis Foundation, Kansas City, MO, 5University of South Florida, Tampa, FL, 6University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Urticarial vasculitis is a markedly rare disease, with an annual incidence of < 1 per million. Hypocomplementemia is associated with systemic features and a…
  • Abstract Number: 0243 • ACR Convergence 2022

    Real World Evidence of Treatment Effectiveness and Unfavorable Clinical Events for Elderly-onset Early Rheumatoid Arthritis in Japan: Results from the IORRA Study

    Naohiro Sugitani1, Eiichi Tanaka1, Eisuke Inoue2, Kotaro Watanabe3, Mai Abe3, Eri Sugano3, Kumiko Saka3, Moeko Ochiai3, Rei Yamaguchi3, Katsunori Ikari4 and Masayoshi Harigai1, 1Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, 2Research Administration Center, Showa University, Shinagawa-ku, Japan, 3Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Shinjuku-ku, Japan, 4Department of Orthopedic Surgery, Tokyo Women’s Medial University School of Medicine, Shinjuku, Japan

    Background/Purpose: The number of elderly patients with rheumatoid arthritis (RA) has been constantly increasing. As of December 2021, 50.3% of the patients with RA who…
  • Abstract Number: 1645 • ACR Convergence 2022

    Evaluating the Use of Genetic Risk Scores as Part of an Integrated Risk Tool for Predicting Coronary Artery Disease in Patients with Rheumatoid Arthritis

    Mehreen Soomro1, Michael Stadler1, Sebastien Viatte1, Alex Macgregor2, Suzanne Verstappen1, Anne Barton1 and John Bowes1, 1The University of Manchester, Manchester, United Kingdom, 2The University of East Anglia, Norwich, United Kingdom

    Background/Purpose: Patients with rheumatoid arthritis (RA) have a higher prevalence of coronary artery disease (CAD) than the general population, which contributes to early mortality. However,…
  • Abstract Number: 0309 • ACR Convergence 2022

    Long-Term Safety and Efficacy of Olokizumab in Patients with Rheumatoid Arthritis – Results of an Open-Label Extension Study

    Eugen Feist1, Evgeny Nasonov2, Michael Luggen3, Saeed Fatenejad4, Sergey Grishin5, Mikhail Samsonov6 and Roy Fleischmann7, 1Helios Clinic Vogelsang-Gommern, cooperation partner of the Otto von Guericke University Magdeburg, Magdeburg, Germany, 2V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, 3University of Cincinnati College of Medicine, Cincinnati, OH, 4SFC Medica, LLC, Charlotte, NC, 5R-Pharm, Moscow, Russia, 6R-Pharm JSC, Moscow, Russia, 7Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: Olokizumab (OKZ), an IL-6 ligand inhibitor, demonstrated significant improvements in signs and symptoms of RA vs placebo (PL) and non-inferiority to adalimumab (ADA).1-2 Patients…
  • Abstract Number: 1668 • ACR Convergence 2022

    Rheumatic Toxicities of Immune Checkpoint Inhibitors Predict Favourable Tumour Responses in Patients with Advanced Melanoma

    Alana Bruce1, Alexander M Menzies2, Georgina V Long2, Brian Fernandes3 and Fredrick Joshua4, 1Macquarie University, Balaclava, Victoria, Australia, 2Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia, 3Royal Prince Alfred Hospital, Sydney, Australia, 4Macquarie University, Integrated Specialist Medical Care, Sydney, Australia

    Background/Purpose: To estimate the frequency of rheumatic toxicities of immune checkpoint inhibitors (ICI) presenting as de novo or exacerbations of pre-existing rheumatic disease in patients…
  • Abstract Number: 0322 • ACR Convergence 2022

    Are Virtual Cognitive Assessments Comparable to In-person Assessments in a Systemic Lupus Erythematosus Cohort?

    Michelle Barraclough1, Juan Pablo Diaz-Martinez2, Andrea Knight3, Kathleen Bingham4, Jiandong Su2, Mahta Kakvan2, Carolina Munoz2, Maria Carmela Tartaglia5, Leslet Ruttan6, Joan Wither7, May Choi8, Dennisse Bonilla2, Nicole Anderson2, Simone Appenzeller9, Ben Parker10, Patricia Katz11, Dorcas Beaton12, Robin Green6, Ian N. Bruce13 and Zahi Touma2, 1Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Toronto, ON, Canada, 2Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, 3The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 4Centre for Mental Health, University Health Network; Department of Psychiatry, University of Toronto, Toronto, ON, Canada, 5University of Toronto Krembil Neurosciences Centre, Toronto, ON, Canada, 6University Health Network-Toronto Rehabilitation Institute, Toronto, ON, Canada, 7Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada, 8Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, 9Unicamp, Campinas, São Paulo, Brazil, 10Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, 11UCSF, San Rafael, CA, 12Institute for Work & Health, Toronto, ON, Canada, 13Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom

    Background/Purpose: Many in-person research studies, such as ours examining cognitive impairment (CI) in SLE, were paused for safety reasons during the COVID-19 pandemic. To restart…
  • Abstract Number: 1767 • ACR Convergence 2022

    Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study

    Bernhard Hellmich1, Konstantin Neukirch2, Marco Lukas2, Martin Wernitz2, Dominik Beier3 and Dennis Häckl4, 1Department of Internal Medicine, Rheumatology and Immunology, Medius Kliniken, University of Tübingen, Kirchheim Teck, Germany, 2GlaxoSmithKline GmbH & Co. KG, Munich, Germany, 3InGef - Institute for Applied Health Research Berlin GmbH, Berlin, Germany, 4WIG2 GmbH, Leipzig, Germany

    Background/Purpose: EGPA and HES are rare multisystemic diseases associated with eosinophilia. Robust data on the epidemiology and treatment of HES and EGPA are scarce. The…
  • Abstract Number: 0338 • ACR Convergence 2022

    Transitioning from Cutaneous to Systemic Lupus Erythematosus: An Analysis of Incidence and Risk Factors

    Jeffrey X. Yang1, Mehmet Hocaoglu2, Jose A Meade-Aguilar1, Alain Sanchez-Rodriguez1, Mark Denis P Davis3, Hannah Langenfeld4, Cynthia Crowson5 and Ali Duarte-Garcia1, 1Mayo Clinic, Rochester, MN, 2University of Maryland Medical Center, Midtown Campus, Baltimore, MD, 3Mayo Clinic, Rochester, 4Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, 5Mayo Clinic, Eyota, MN

    Background/Purpose: Smoking and use of estrogen-containing oral contraceptives (OCP) are SLE risk factors. Data on transitioning from cutaneous lupus erythematosus (CLE) to SLE and potential…
  • Abstract Number: 1784 • ACR Convergence 2022

    Gait Alterations Associated with Worsening Physical Function over 2 Years: A Machine-learning Approach in the Multicenter Osteoarthritis (MOST) Study

    Kathryn Bacon1, David Felson1, S. Reza Jafarzadeh2, Vijaya Kolachalama2, Jeffrey Hausdorff3, Eran Gazit4, Joshua Stefanik5, Patrick Corrigan6, Neil Segal7, Cora E. Lewis8, Michael Nevitt9 and Deepak Kumar1, 1Boston University, Boston, MA, 2Boston University School of Medicine, Boston, MA, 3Tel Aviv University, Tel Aviv, Israel, 4Tel Aviv Suarasky Medical Center, Tel Aviv, Israel, 5Northeastern University, Boston, MA, 6Saint Louis University, St. Louis, MO, 7University of Kansas, Kansas City, KS, 8University of Alabama at Birmingham, Birmingham, AL, 9University of California at San Francisco, Orinda, CA

    Background/Purpose: Altered gait is related to pathogenesis of knee osteoarthritis (OA). For people with knee OA, in addition to pain, declines in physical function are…
  • Abstract Number: 0342 • ACR Convergence 2022

    Multi-Parametric Interrogation of the Systemic Lupus Erythematosus (SLE) Immunome Reveals Multiple Derangements

    Katherine Nay Yaung1, Joo Guan Yeo2, Hui Nee Annie Law3, Martin Wasser4, Thaschawee Arkachaisri5, Julian Thumboo3, Andrea Low3 and Salvatore Albani4, 1Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre, Singapore; Duke-NUS Medical School, Singapore, Singapore, 2KK Hospital, Singapore; Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre, Singapore, Singapore, 3Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, 4Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre, Singapore, Singapore, Singapore, 5KK Women's and Children's Hospital, SingHealth, Singapore, Singapore

    Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, systemic autoimmune disease that interferes with the balance between regulation and immunity, resulting in immune system dysfunction.…
  • Abstract Number: 1842 • ACR Convergence 2022

    Vaccination in Patients with Autoinflammatory Periodic Syndromes Under Canakinumab – Safety Data Interim Analysis of the RELIANCE Registry

    Jasmin B. Kuemmerle-Deschner1, Joerg Henes2, Birgit Kortus-Goetze3, Tilmann Kallinich4, Prasad T. Oommen5, Juergen Rech6, Tobias Krickau7, Frank Weller-Heinemann8, Gerd Horneff9, Ales Janda10, Ivan Foeldvari11, Catharina Schuetz12, Frank Dressler13, Michael Borte14, Markus Hufnagel15, Florian Meier16, Michael Fiene17, Julia Weber-Arden18 and Norbert Blank19, 1Department of Pediatrics, Division of Pediatric Rheumatology, University Hospital Tübingen, Tübingen, Germany, 2Center for Interdisciplinary Clinical Immunology, Rheumatology and Auto-inflammatory Diseases (INDIRA), University Hospital Tübingen, Tübingen, Germany, 3Division of Nephrology, University of Marburg, Marburg, Germany, 4Charité - Universitätsmedizin Berlin, Nuremberg, Germany, 5Clinic of Pediatric Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, 6University Clinic Erlangen, Erlangen, Germany, 7Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Pediatrics, Erlangen, Germany, 8Klinikum Bremen-Mitte, Prof. Hess Kinderklinik, Bremen, Germany, 9Pediatrics, Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, 10Department of Pediatrics, University Hospital Ulm, Ulm, Germany, 11Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, 12Pediatrics, Medizinische Fakultaet Carl Gustav Carus, Technische Universitaet Dresden, Dresden, Germany, 13Division of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany, 14ImmunoDeficiencyCenter Leipzig (IDCL), Hospital St. Georg gGmbH Leipzig, Germany, Leipzig, Sachsen, Germany, 15Division of Pediatric Infectious Diseases and Rheumatology, Department of Pediatrics and Adolescent Medicine, University Hospital Medical Center Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany, 16Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt, Germany, 17Rheumatology Center Greifswald, Greifswald, Germany, 18Novartis Pharma GmbH, Nuernberg, Germany, 19Rheumatology, University Hospital Heidelberg, Heidelberg, Germany

    Background/Purpose: Treatment of autoinflammatory periodic syndromes with the interleukin-1β inhibitor canakinumab (CAN) has been shown to be safe and effective in clinical trials and in…
  • Abstract Number: 0362 • ACR Convergence 2022

    The Renal Activity Index for Lupus (RAIL) Identifies Active Renal Disease in SLE Patients and Its Longitudinal Score Associates with Renal Responses in Lupus Nephritis

    Hermine I. Brunner1, Catharina Lindholm2, Ellen Cody1, Prasad Devarajan1, Bin Huang1, Dominic Sinibaldi3, Madhu Ramaswamy3, Jacob Knagenhjelm4, Tingting Qiu1, Frederick Jones5, Philip Brohawn3, Raj Tummala3 and Wendy White3, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2AstraZeneca, Gothenburg, Sweden, 3AstraZeneca, Gaithersburg, MD, 4AstraZeneca, Gateborg, Sweden, 5AstraZeneca, Cambridge, United Kingdom

    Background/Purpose: LN confers poor prognosis, and there is a lack of effective non-invasive tests to assess disease activity and treatment response. We previously showed that…
  • Abstract Number: 1933 • ACR Convergence 2022

    PECOS (Pediatric SARS-CoV-2 MIS-C Long-term Outcomes Study): Preliminary Results

    Gina Montealegre Sanchez1, Roberta DeBiasi2, Lauren Arrigoni2, Kevin Rubenstein3, Jason Liang4, James Bost2, Marcin Gierdalski2, Max Wolff3, Mallory Barrix2, Maureen Edu2, Saira Huq2, Shera Weyers3, Patricia Bandettini5, Dorothy Bulas2, Tom Burklow6, Marcus Chen5, Sanchita Das6, Robin Dewar3, Joseph Fontana5, Ashraf Harahsheh2, Linda Herbert2, Anastassios Koumbourlis2, Andrew Lipton5, Laura Olivieri2, Dinesh Pillai2, Vandana Sachdev5, Craig Sable2, Audrey Thurm7, Evrim Turkbey6, Alexandra Yonts2, Jonathan Zember2, Eric Vilain2, Meghan Delaney2, Luigi Notarangelo4, David Wessel8 and Karyl Barron4, 1NIAID/NIH, Garrett Park, MD, 2Children's National Hospital, Washington, DC, 3Frederick National Laboratory for Cancer Research, Frederick, MD, 4NIAID/NIH, Bethesda, MD, 5NHLBI/NIH, Bethesda, MD, 6CC/NIH, Bethesda, MD, 7NIMH/NIH, Bethesda, MD, 8Children's National Hospital, Washington, MD

    Background/Purpose: The long-term complications of SARS-CoV-2 and MIS-C in children are unknown. PECOS, a joint study at the National Institutes of Health (NIH) Clinical Center…
  • Abstract Number: 0143 • ACR Convergence 2021

    Economic and Healthcare Resource Use Burden of Systemic Sclerosis

    Dinesh Khanna1, Dan Furst2, Justin Li3, Qian Meng4, Tamara Lesperance5, Kenyatta Peoples6, Farah Ali5, Brian LaMoreaux5 and Stephanie Taylor7, 1University of Michigan, Ann Arbor, MI, 2University of California Los Angeles, Los Angeles, CA, 3Trinity Partners, Waltham, MA, 4Trinity Life Sciences, Waltham, MA, 5Horizon Therapeutics plc, Deerfield, IL, 6Horizon Therapeutics plc, Lake Forest, IL, 7Horizon Therapeutics plc, Whitehouse Station, NJ

    Background/Purpose: The clinical burden of systemic sclerosis (SSc) is substantial and typically characterized by progressive skin, gastrointestinal, pulmonary, and cardiovascular complications and premature death. The…
  • Abstract Number: 1220 • ACR Convergence 2021

    Identification of Underlying Disease Domains by Longitudinal Latent Factor Analysis for Secukinumab Treated Patients in Psoriatic Arthritis and Rheumatoid Arthritis Trials

    Xuan Zhu1, Fabian Falck2, Sahra Ghalebikesabi2, Matthias Kormaksson1, Marc Vandemeulebroecke3, Cong Zhang1, Luis Santos4, Chun Hei Kwok4, Dominique West4, Ann-Marie Mallon4, Ruvie Martin1, Aimee Readie1, Kunal Gandhi1, Gregory Ligozio1 and George Nicholson2, 1Novartis Pharmaceuticals Corporation, East Hanover, NJ, 2University of Oxford, Oxford, United Kingdom, 3Novartis Pharma AG, Basel, Switzerland, 4MRC Harwell Institute, Harwell Campus, Oxfordshire, United Kingdom

    Background/Purpose: Secukinumab is a fully monoclonal antibody approved for the treatment of several related autoinflammatory diseases, including psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis.1 While…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 17
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology